Posts

Bristol Myers Ends Cellares Manufacturing Deal as Cell-Therapy Company Reorganizes

on

Lilly bets $3B+ to add China's Haisco to growing list of partners in five‑program pact – June 2–3, 2026 update

on

Parabilis reveals IPO plans the day after Regeneron deal as listings heat up

on

Crown Bioscience and Turbine Partner to Connect AI-Driven Prediction with Organoid Validation in Translational Oncology

on

Novo Nordisk Partners with OpenAI to Accelerate Drug Development

on

Biodexa Announces Partnership with Syngene to Manufacture MTX240 GMP Clinical Trial Supplies

on

Gilead Declines Option on Assembly Biosciences' Phase 1 HBV Antiviral ABI-4334

on

Sandoz Expands Biosimilar Collaboration with Samsung Bioepis, Targeting Takeda's Entyvio

on

Unnatural Products Secures Novartis Partnership Worth Up to $1.8 Billion for Macrocyclic Peptide Therapeutics in Cardiovascular Disease

on

kyron.bio Announces Strategic Partnership with Servier to Advance Precision Glycosylation in Antibody Therapeutics

on

Novo Nordisk Partners with Langer-Founded Vivtex on Oral Obesity Drugs in $2.1B Deal

on

Novartis Partners with Unnatural Products on Up to $1.8B Macrocyclic Peptide Deal for Cardiovascular Therapeutics

on

Reperio Health and Amazon One Medical Partner to Streamline At-Home Preventive Care

on

Zealand Pharma and OTR Therapeutics in multi-program strategic collaboration for metabolic diseases

on

Tessera Therapeutics Strikes $150M Partnership with Regeneron for Gene Writing Therapy

on

Tessera Therapeutics Advances Gene Writing Technology with Major Funding and Strategic Partnerships

on

Korro Bio Abandons Lead Genetic Disease Drug Candidate KRRO-110 After Disappointing Trial Data

on

Neuphoria Scraps Social Anxiety Drug After Trial Failure; Minerva Doubles Down on Schizophrenia Therapy

on

Novo Nordisk Ends Cell Therapy Research Amid Major Restructuring

on

CSL Commits $117M for Option to Acquire VarmX and Advance Novel Blood Clotting Therapy to Market

on